Some of biology's biggest breakthroughs began with a scientist noticing something odd. An enzyme found in a Yellowstone hot spring became the backbone of modern DNA testing. A strange repeating pattern in bacterial DNA became CRISPR, a discovery that gave rise to a whole class of gene-editing companies.
Now, an artificial intelligence (AI) model has noticed something odd. The breakthrough raises a fair question for investors in Beam Therapeutics (BEAM). If AI can help accelerate medical innovation, are biotech companies under threat right now?
